Based on the described crosstalk between H1 receptor signaling and GR activity, antihistamines could be repositioned as adjuvants for GC‐based therapies to diminish their adverse effects.45 Considering the widespread use of both types of drugs, the repositioning of antihistamines may make available new and safer therapeutic strategies, offering new options to improve the management of the symptoms in patients with asthma and other related inflammation‐related respiratory conditions. The gene discussed is NR3C1; the disease is asthma.